OpenAI appears to have moved beyond simply detailing its models' capabilities. The company is now favoring narratives that blend reality with captivating tales, substituting scientific evidence with impressive pronouncements. A recent prominent example involves a personalized mRNA vaccine designed to treat cancer in a dog. OpenAI CEO Sam Altman and VP of Science Kevin Weil have enthusiastically promoted this case, calling it a "glimpse into the future" where AI accelerates personalized medicine. They suggested that chatbots empowered the dog's owner with the "might of a research institute." This narrative, predictably, garnered significant attention, with a post on X accumulating 1.3 million views. However, a critical detail was omitted: neither Altman nor Weil provided any evidence to support the vaccine's efficacy.
Instead of rigorous scientific data, the company relied on persuasive language and references to "amazing meetings." The dog's owner, Paul Cunningham, did indeed utilize ChatGPT and AlphaFold in his search for treatment for his pet, Rosie. He invested in costly whole-genome sequencing ($3,000) and, guided by the chatbot's advice, developed a treatment protocol. The AI reportedly helped identify a target protein and suggested an existing compound. Crucially, this occurred concurrently with the administration of an approved immunotherapy drug, a PD-1 inhibitor. Experts largely attribute Rosie's improved condition to this established treatment. The likelihood that the AI-assisted, self-assembled mRNA vaccine played a decisive role is considered negligible. Nevertheless, OpenAI seems to prioritize compelling storytelling over scientific validation.
This instance appears to be more than an isolated event; it may represent a deliberate strategy. When genuine breakthroughs are infrequent, and both investors and the public crave miraculous outcomes, companies like OpenAI actively cultivate "scientific hype." They construct a narrative positioning AI not just as a tool, but as a magical solution to complex problems. This approach involves making bold claims while downplaying skepticism. Veterinarian Egan Pellant directly addressed the lack of evidence, describing the situation as "storytelling for AGI believers looking for venture capital money." As long as such narratives capture attention and, consequently, potential investment, the demand for verifiable data may be secondary to crafting a desired image and proclaiming a new era.
Why this matters: For CEOs and entrepreneurs making AI investment decisions, the ability to distinguish between hype and actual results is paramount. Rather than being swayed by appealing stories, you must demand scientific substantiation and measurable KPIs. Ignoring this fundamental practice risks resource misallocation and missing out on genuine competitive advantages. In a market where public relations can obscure a lack of progress, sober analysis and a focus on proven outcomes become your essential tools for strategic decision-making.